



England

South East Region Community Pharmacy MenB Vaccination Webinar- 08/07/2026

**NHSE South East Region
Public Health Commissioning Team**



Agenda

Topic	Presenter
Welcome and introductions (housekeeping)	Helen Wardle
Meningococcal disease and MenB vaccination	Amanda Wright
Eligibility	Amanda Wright
Scheduling	Rowan Maddock
MenB vaccine	Rowan Maddock
Vaccine administration, supply, contraindications	Rowan Maddock
Reporting incidents and queries	Rowan Maddock
CP sign up and Advanced Service	Helen Wardle
Vaccination IT Platforms	Helen Wardle
Patient and professional resources	Helen Wardle
Q&A - if your MenB query is in relation to any of the subjects above please wait until we have covered that section	Lucy Pylypiw




Welcome and introduction

- Welcome to the webinar – the NHSE South East Public Health Commissioning Team will be providing an overview of the time-limited Meningococcal B (MenB) vaccination programme for young people
- The webinar is aimed at health professionals involved in the commissioning and delivery of the MenB vaccination programme
- Please **do not** use AI tools to record the webinar, this allows attendees to speak freely when asking any questions
- The webinar will be recorded and shared via Futures
- Both webinars will have the same content
- Slides will be shared with attendees following the second webinar
- There will be a Q&A at the end of the webinar

Housekeeping

- Thank you to those who submitted questions in advance. We will only be answering general questions relating to the MenB vaccination programme. Any individual clinical queries or other general vaccination queries should be emailed to your local SVOC (contact details at end of slides).
- Q&A function is open on Teams, please add your questions there as we go along, and we will answer questions at the end of the webinar. Please avoid raising your hand as we have disabled all mics and cameras due to the number of attendees. Please use the Q&A function.





SE Region Public Health Commissioning Team

The NHSE SE Region Covid Vaccination Team and NHSE SE Region Screening and Immunisation Teams (SITs) (both part of the SE Public Health Commissioning Team) are working to coordinate delivery of the time-limited MenB vaccination programme.

SITs provide clinical and public health support for the commissioning of high-quality national screening and immunisation programmes. They ensure that NHS screening and immunisation programmes are coordinated, safe, effective and accessible. There are 4 SITs in the South East region: Hampshire and Isle of Wight, Kent and Medway, Surrey and Sussex, and Thames Valley.

NHS immunisation programmes that the SITs support include: childhood immunisations, school aged immunisations, adult immunisations, maternal immunisations, selective immunisation programmes for those at risk including neonatal hepatitis B, neonatal BCG and seasonal immunisations.



Background and outline of MenB vaccination programme

- Following the unprecedented MenB outbreak in March 2026, primarily among University of Kent students, and clusters in Weymouth and Reading, NHSE/UKHSA has announced a new one-off and time-limited offer of MenB vaccination for those considered at highest risk.
- The programme will start on 20 July 2026 (first doses to be completed by 31 December 2026, and second doses by 31 March 2027).
- The aim is to vaccinate individuals before the start of the 2026/2027 academic year and the peak season for MenB in autumn 2026.
- Those entering university for the first time and who are under the age of 25 are considered at highest risk from MenB disease.
- Community pharmacies have been commissioned to deliver this one-off programme.



Meningococcal disease

- Meningococcal disease is caused by invasive infection with the bacterium *Neisseria meningitidis* (N. meningitidis).
- The bacteria strains, B, C, W and Y were historically the most common cause of invasive meningococcal disease (IMD) in the UK.
- IMD is rare but extremely serious, most commonly presenting as either meningitis or septicaemia, or a combination of both.
- Meningococci commonly colonise the nasopharynx of humans and usually do not cause invasive disease.
- Between 5% and 11% of adults and up to 25% of adolescents carry the bacteria without any signs or symptoms of the disease, although carriage rates appear to be lower in more recent studies. In infants and young children, the carriage rate is low.
- The meningococci are transmitted by respiratory aerosols, droplets or by direct contact with the respiratory secretions of someone carrying the bacteria. (Coughing, sneezing, kissing, sharing drinks or vapes).
- The incubation period is from 2 to 7 days and the presentation of disease ranges from severe acute and overwhelming features, to insidious with mild symptoms.



Meningococcal disease continued

Symptoms include:

- Fever
- A stiff neck / joint or muscle pain
- Severe headache
- Sleepiness / difficult to wake
- Unable to look at bright lights
- Vomiting
- Confusion
- A rash that does not fade.

Meningococcal disease requires urgent hospital treatment, including antibiotics and IV fluids

Most people who receive prompt treatment make a full recovery, but some experience long-term complications including hearing loss, memory problems, or loss of limbs.

In 2024/25 the case fatality ratio in England was 8.2% of laboratory confirmed cases.



Effectiveness of Meningococcal B vaccination

Bexsero® (4CMenB) vaccine is the only vaccine being used for this programme. Two doses are required for protection.

Research from Australia shows that Bexsero® (4CMenB) provides around five years of protection after the second dose.

The study goes on to say vaccine efficiency against Meningitis B disease for the 3-dose schedule was 98.5% (95% CI, 81.9%–99.9%) in children and **92.3% (34.3%–99.1%) for the 2-dose vaccination in adolescents.**

You can find the study here:

Wang B, Giles L, Andraweera P and others. Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study. Clinical Infectious Diseases: July 11 2025, volume 81, issue 4, pages 202 to 210


Who will be eligible for the vaccine?

Born between
1 September 2007
and
31 August 2008
(current school year
group 13)

Born on or after 21
July 2001
AND
Entering Higher
Education or
Residential Further
Education (HERFE) for
the first time in
Autumn 2026

Who is not eligible for the vaccine?

- those aged less than 25 years, **who are not entering HERFE* for the first time** in the autumn term 2026, and fall outside the current year 13 age group specified above
- postgraduates and other students **who are not entering HERFE for the first time** in the autumn term of 2026
- those who completed a 2-dose course of Bexsero® within the last 5 years
- those who completed a 2-dose (provided those doses were given at least 6 months apart) or 3-dose course of Trumenba within the last 5 years



How will the eligible cohort present?

The current school year 13 cohort (born between 1 September 2007 and 31 August 2008) will be contacted directly through the NHS app or by text, email or letter depending on records held by the NHS. These messages will include details of how to book an appointment at a pharmacy via NBS.

Those born on or after 21 July 2001 **and** entering HERFE for the first time in Autumn 2026 will be self-referrals.

A public information campaign will raise awareness among eligible groups.

UCAS will be emailing all individuals who have applied to university to outline the offer.

Pharmacy owners may want to consider how they promote the availability of the service to their patients and their community using any appropriate tools and resources they have at their disposal (see resources links at end of slides).

Acceptable evidence of eligibility

Current school year 13 age group eligibility criteria:

ALL young people who were born between 1 September 2007 and 31 August 2008. (*This cohort can be identified by the date of birth documented in their clinical records*)

HERFE* entrants eligibility criteria :

Young people who born on after 21 July 2001 **and** present acceptable evidence at their vaccination appointment that they are due to attend HERFE for the first time in the academic year 2026/2027 (this includes international students and those from the UK devolved administrations and Crown Dependencies) as follows:

- official email confirmation of their offer of a place at their chosen university or college from either the higher education (HE) institution (usually a .ac.uk email address) or the Universities and Colleges Admissions Service (UCAS)
- a letter (hard copy or email) confirming they have received an offer of a place for the 2026/2027 academic year at their chosen university or college
- screenshot of their offer of a place at their chosen university or college from the UCAS Hub

The relevant evidence should include the name of the university or college that they are due to attend, the course code and/or title of the course of study, and confirmation of the offer of a place (either conditional or unconditional).

Those working in clinical settings should, in addition, consult a list of residential further education settings from which students in England are eligible, to inform a decision as to whether or not to administer MenB vaccination. [List of eligible residential FE settings](#)



Scheduling information for one off programme

The recommended schedule for Bexsero® vaccine is 2 doses, with the second dose given a minimum of 28 days after the first dose.

Vaccination courses delivered to young people as part of the recent MenB outbreak responses may mean that some individuals present to clinics having already received at least one dose of MenB (Bexsero®) vaccination. It is also likely that some of the eligible cohort may have taken up at least one dose via the private market. International students may have received a dose or course of vaccination outside of the UK.

Where an eligible individual is uncertain about their vaccination history and is unable to produce any evidence of prior vaccination when they present, a 2-dose course of Bexsero® should commence rather than risk leaving them unprotected. Common questions and scenarios are covered in the guidance for healthcare practitioners here: [MenB time limited vaccination offer: information for healthcare practitioners - GOV.UK](#)

It is also important to remind them of the need to complete MenACWY vaccination before attending university and catching up any missed vaccines like HPV and MMR. Guidance on vaccination of individuals with unknown or incomplete vaccination status is found here: [Annex A: detailed information, guidance and resources for healthcare professionals - GOV.UK](#) these can be arranged by contacting their GP.

Information about the MenB vaccine (Bexsero®)

- Bexsero® (4CMenB) is a Meningococcal group B vaccine.
- It is a 4-component protein-based meningococcal B vaccine.
- It is given to individuals from 2 months of age and older to help protect against disease caused by the *Neisseria meningitidis* group B bacteria. These bacteria can cause serious, and sometimes life-threatening, infections such as meningitis (inflammation of the covering of the brain and spinal cord) and sepsis (blood poisoning).
- The vaccine works by specifically stimulating the body's natural defence system of the vaccinated person. This results in protection against the disease.
- https://public.gsk.co.uk/products/bexsero/bexsero_overview.html
- Bexsero® vaccine is supplied as a white opalescent liquid suspension (0.5mL) in a pre-filled syringe (10-dose pack) for injection.
- **(NOTE: Needles are NOT included and will need to be ordered separately- at the pharmacy's expense).** Use a 25mm 23G or 25G needle (not supplied with vaccine) (see [training slideset](#))
- Further information can be found in the [Summary of Product Characteristics](#) (SPC).





Vaccine administration

- Bexsero® is given as a 0.5ml dose by intramuscular injection usually into the deltoid muscle region of the upper arm in older individuals.
- The vaccine is a white opalescent liquid suspension. Upon storage, a fine off-white deposit may be observed in the pre-filled syringe containing the suspension.
- Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension.
- The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.
- In line with general advice about co-administration of inactivated or non-live vaccines, Bexsero® can be given at the same time as any other vaccines required (with the exception of Trumenba, MenB vaccine). Please see guidance: [Green-Book-Chapter-4.pdf](#) and [MenB time limited vaccination offer: information for healthcare practitioners - GOV.UK](#)
- The vaccine's SPC provides further guidance on administration and is available from the [Home - electronic medicines compendium \(emc\)](#) website.

PGD

- The PGD has been uploaded to [MenB vaccine \(Bexsero®\) offer Autumn 2026: PGD template - GOV.UK](#)
- NHS England has authorised this PGD for use by the services or providers delivering the national 4CMenB time-limited offer Autumn 2026 vaccination programme.
- This is the **only** legal mechanism for delivering this programme.
- Only section 7 can be completed within the editable fields with the responsibilities and governance arrangements of the organisation.
- Individual practitioners must be authorised by name, under the current version of this PGD before working according to it.
- Registered professionals with one of the following bodies can work under this PGD:
 - nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)
 - pharmacists and pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC) (Note: this PGD is not relevant to privately provided community pharmacy services)
 - paramedics, physiotherapists, dieticians, podiatrists, and occupational therapists currently registered with the Health and Care Professions Council (HCPC)

Training

UKHSA have developed a [Meningococcal B \(MenB\) time limited vaccination offer: training slideset](#)

The aim of the resource is to:

- to raise awareness of invasive meningococcal disease (IMD) epidemiology and symptoms
- to support and educate healthcare professionals involved in discussing vaccination against meningococcal B disease
- to support the safe vaccination of individuals who present for this time-limited meningococcal B vaccine programme

Before administering vaccines, it is recommended that vaccinators will have:

- undertaken training in the management of anaphylaxis and Basic Life Support
- received practical training in vaccine preparation and administration
- completed a vaccinator competency assessment tool – [please refer to National minimum standards and core curriculum for vaccination training](#)

Possible adverse reactions



Common side effects

It is common to get some swelling, redness or tenderness where you have the injection. You may also get a mild fever, nausea, headache or muscle aches but these symptoms should disappear after one or two days.

You can take over the counter pain medication such as paracetamol to manage these symptoms if needed. More serious side effects are rare.


- The most common local and systemic adverse reactions observed in adolescents and adults are swelling, redness and tenderness at the injection site.
- Other common side effects include mild fever, nausea and headache or muscle aches.
- Serious side effects are rare.
- All clinical staff administering vaccinations should be able to recognise the symptoms or signs of an allergic reaction and specifically anaphylaxis, to call for help and to start treatment. In every location where vaccines are being given, an anaphylaxis pack should be immediately available.
- Bexsero® is no longer subject to additional monitoring under the black triangle labelling scheme by the (MHRA) [Medicines and Healthcare products Regulatory Agency - GOV.UK](#)
- All suspected serious adverse reactions should continue to be reported to the MHRA using the Yellow Card scheme. [Yellow Card | Making medicines and medical devices safer](#)
- [A guide to Meningococcal B vaccination for eligible young people - GOV.UK](#)

Contraindications

- There are very few individuals who cannot receive meningococcal vaccine.
- The vaccines should not be given to those who have had:
 - a confirmed anaphylactic reaction to a previous dose of the vaccine
 - a confirmed anaphylactic reaction to any component or residue from the manufacturing process

Please see [chapter 22 of the Green Book](#) and [SPC](#) for more information.

[A guide to Meningococcal B vaccination for eligible young people - GOV.UK](#)



Reporting Covid, Flu and 'time limited' MenB programme incidents

- Report **all** incidents including cold chains within **48 hrs**. Incidents with moderate or significant impact should be reported on the **same day**.
- All **incident/cold chains/queries** (including clinical and operational queries) should be sent via the **local ICB SVOC** (System Vaccination Operations Centre). There are some exceptions – please see the Q&A slide.
- For incidents, submit the completed [incident](#) or [cold chain](#) form to your ICB SVOC, who will forward it to the South East Regional Operational Centre (ROC) for review by the clinical team:
 - Sussex: sxicb.primarycaremassvacc@nhs.net
 - Surrey Heartlands: syheartlandsicb.svoc@nhs.net
 - Thames Valley ICB: svoc-opsmanager.bob@nhs.net
 - Hampshire/IOW ICB: hiowicb-hsi.vaccination.operations@nhs.net
 - Kent & Medway ICB: kmicb.svoc@nhs.net

MenB incident guidance will be provided by your SIT. Guidance also available: [UKHSA Vaccine Incident Guidance](#)

Registration for the MenB Programme

Please see [here](#) for the MenB service specification following the Government's recent announcement of [a new one-off, time-limited Meningococcal B \(MenB\) vaccination service for those considered at highest risk](#).

The Item of Service fee is £10.06 per administered vaccination to an eligible individual. Recognising the considerable effort it will take to stand up this new service and to maximise uptake, community pharmacies will also be eligible for additional payments of:

- £300 - if at least one vaccination is administered
- AND
- £400 - if at least 100 vaccinations are administered

Community pharmacies have until **23:59** on **20 July 2026** to sign up to deliver this service using this registration form: [Registration for the Community Pharmacy Advanced Service: Meningococcal B Vaccination](#).

Pharmacies must sign up by 6 July 2026 to be guaranteed vaccine supply for the start of the programme on 20 July 2026. Any registration received after the deadline will not be accepted and the pharmacy contractor will not be able to provide the service.



Federated Data Platform (FDP)

The vaccine deployment model will utilise the NHSE Supply Chain and will require providers to order using the Federated Data Platform (FDP). Some providers will be familiar with this methodology (due to the use of FDP for COVID and childhood flu vaccines).

Providers needing system access to FDP (i.e. if have never received COVID or children's flu vaccines or require user-level access) should complete [Vaccination Provider System Access Request – Fill in form](#) - this is generic for any programme where the provider needs access. **This form is also used for access to MYA.**

Stock should not be used for Private Vaccinations.

Movement of stock is not allowed. Please plan your stock.

If existing Bexsero stock was not centrally sourced, then NHSE will not reimburse the cost of vaccine bought privately from manufacturer.



Federated Data Platform - Access and Vaccine Supply

The 4CMenB vaccine, for Patients, is centrally supplied and must be ordered via FDP. Pharmacy contractors must register for FDP to be able to order vaccines. This vaccine is supplied free of charge and will not be reimbursed as part of the AS. [Accessing the NHS Federated Data Platform \(FDP\) | Rise 360](#)

Users need to request access to FDP – We recommend at least two per Pharmacy. Access requests will be approved by Region. Please do not use Generic Email addresses as these will be rejected. If you are new to FDP you will also need to complete an acknowledgment page in the Supply planner to confirm the pharmacy details.

The pharmacy contractor must ensure that all orders of 4CMenB vaccine are in line with national ordering restrictions. Pharmacy contractors will be able to place their first order of a **minimum quantity of 10 4CMenB vaccines** (single pre-filled syringe which are supplied in a pack of 10) of centrally supplied 4CMenB vaccine via the FDP if they comply with the requirements by adding NBS appointments. This is 100 appointments per month. The pharmacy contractor must register for the service by 6 July 2026 if they would like to start offering appointments on NBS from the Service Commencement Date and providing the pharmacy contractor has a minimum of one booking made via NBS from 20 July, they will receive stock on time to administer it to the Patient.



Vaccine Supply

You must order your own vaccine supply. You must comply with the AS criteria for vaccine supply to be delivered.

Pharmacy contractors may only request subsequent supply of 4CMenB vaccine when:

6.4.1. the pharmacy has recorded use of at least 50% of the previously supplied doses for any vaccinations administered before 31 December 2026 and 70% for any vaccinations administered after 31 December 2026; and

6.4.2. current stock levels are confirmed to be below 1 pack (i.e. less than 10 pre-filled syringes); and

6.4.3. appointments listed on NBS comply with paragraph 4.16; or 6.4.4.

NBS booked appointments indicate a need for additional supply. Any order that does not meet the requirements in paragraph 6.4 will be deferred until the pharmacy contractor evidences that they have been met.

Please ensure you keep vaccine stock for booked appointments. Do not use booked vaccine for walk ins. Only surplus stock can be used for walk ins.



Vaccine Supply and Stock Take

If your pharmacy has met all of the criteria you will be able to order vaccine via the Supply Planner.

Please note there will be fixed delivery days for MENB. Please check your supply planner for your fixed delivery day. Please ensure you can receive vaccine in time for your first appointments.

There will be NO emergency or short time frame deliveries.

ETA will not show in the supply planner as you are familiar with for covid deliveries – there will be a link that you can click on to get ETA for vaccine delivery

STOCK TAKE

All stock must be actively managed, with vaccine usage reported in FDP in a timely manner. Pharmacy contractors must not stockpile vaccine.

You must submit a valid stocktake in FDP within 7 days of any requests for additional vaccine.

Failure to report vaccine usage or stock levels accurately may result in temporary suspension of supply.

Failure to submit a stock take will also result in cancelled clinics.



Allocations

Allocation Model

There is no season forecast model. All providers start with a flat initial allocation of 10 doses regardless of size or historical activity. Subsequent allocations are either a further 10 doses or a quantity matching NBS booked appointments. The programme is designed for a specific, time-limited cohort of approximately one million young people, so allocations are tightly managed and linked directly to appointment activity. Walk-in activity can be served using surplus stock only. Providers will not receive allocations to cover walk-in activity, and additional supply requests made solely for this purpose will not be approved.

Ordering Flexibility and delivery dates

Unlike COVID-19, providers can only place orders for delivery on their assigned fixed delivery day each week. There are no off-schedule deliveries under any circumstances.

Order cut-off deadlines

Cut-off deadlines are fixed and tied to your delivery day. Missing the cut-off means waiting until your next scheduled delivery day. There are no exceptions.

Triggering a new allocation

There is no TDM or season forecast release mechanism. A new allocation is triggered once a provider has vaccinated at least 5 patients (50% of the initial 10-dose pack).

Consumables

Unlike the COVID-19 programme, consumables including suitable needles are not centrally supplied. You are responsible for sourcing and funding your own consumables.



Site Acknowledgment Page

MENB vaccine will be requested and supplied through the Supply Dashboard on the Federated Data Platform (FDP). You must check your details are accurate to ensure vaccines will be delivered correctly and safely. **If this is not completed you will not receive vaccine. Please note your FDP access request must be approved before you can complete this step.**

You must check that the following information is correct on the Supply Dashboard:

- Your site lead contact NHSmail email and mobile phone number
- Site address
- Fridge capacity
- To check your details please go to the [Supply Dashboard](#) on FDP.
- If there are any inaccurate details please follow the below instructions:
- Site contact details and fridge capacity: **You** can update these directly in FDP
- Site address: Email england.sepharmacycovidvacc@nhs.net and ask for this to be amended and include full details.

FDP Support

- FDP help guides are available throughout the platform via the “?” icon.
- Additional training materials are available at [Federated Data Platform Training Materials](#).
- For access issues, contact ssd.nationalservicedesk@nhs.net or log a ticket using the [Customer Portal](#).
- To remove a user from FDP, please provide the e-mail address of that user to ssd.nationalservicedesk@nhs.net

A Vaccine Supply and Ordering Guidance for Providers is being published and will be circulated tomorrow.

Recording vaccinations

Community Pharmacy MUST use Record A Vaccination Service (RAVS). Vaccination events recorded in RAVS will flow to GP records.

How to sign up to RAVS

- You need to sign up for a RAVS account by going to the [Record a vaccination website](#). There are two parts to signing up RAVS sign up and OKTA. Please ensure you do both.

Further information about RAVS

For general information about RAVS, go to the:

- [Record a vaccination website](#)
- [Record a vaccination user guide](#) (includes short training videos) **We recommend you watch the short video.**

For questions about signing up to RAVS, [join a drop-in session with the onboarding team](#). **We recommend you attend a drop in if you have any questions regarding sign up. Please ensure you have watched the video as this may help with questions you may have.**

The Drop in dates and times are:

9 July – 11.30am-Midday 14 July – 5pm-5.30pm 23 July – 2.30pm-3pm 4 August 5pm-5.30pm

Helpdesk Support

[Customer Service Portal - Customer Support](#)



NBS and Walk in Finder

NBS

The pharmacy contractor must offer MenB vaccination appointments through NBS. The pharmacy contractor must comply with the requirements of using the NBS, including ensuring that accurate information is published and appointments or clinic times are uploaded in a timely way to allow Patient bookings to take place. **You can add NBS appointment slots now on to MYA. Patient bookings open on 13 July 2026.**

The minimum publication standards for NBS appointments is 100 appointments per month.

Please ensure that appointments are available at various times throughout the pharmacy's full opening hours, including late afternoons and Saturdays (where the contractor is open on Saturdays).

Walk in Finder

The pharmacy contractor must offer vaccination through advertised walk-in clinics via the Pharmacy Services Finder.



MYA Support

Training materials will be available on [Manage your Appointments on NBS Training Videos](#) – Vaccinations and Screening - Futures and will be supported by drop-in Q&A sessions.

Guidance pages are also available online:

[Manage Your Appointments guidance - NHS England Digital.](#)

To add a temporary (pop-up) site onto **Manage Your Appointments**, please contact your Regional team to add the site onto the approval process through FDP.

MYA Help and Support

- Contact the helpdesk for support via the customer portal and raise a ticket: [NBS Helpdesk](#).
- NBS information, including frequently asked questions and advice, can be found at: [Manage your Appointments - FutureNHS](#).

First dose and second dose

Patients should receive the first dose of the 4CMenB vaccine as soon as possible after the Service Commencement Date in order for them to be able to receive the second dose of the vaccine ideally before the start of the 2026/27 academic year.

The first dose of the 4CMenB vaccine must be administered before **31 December 2026** to allow sufficient amount of time for the second dose to be administered before the End Date of this AS which is **31 March 2027**.

The second dose should be administered at least **28 days** after the first dose.

You must administer at least 10 vaccines between **20 July and 30 September 2026** or the Commissioner may suspend supply of vaccine.



Patients with No NHS Number or GP Registration

Patients **do not** require an NHS number **or** general practice registration and should not be denied vaccination on this basis.

The vaccine is to be administered by an appropriately trained vaccinator, authorised to use the relevant legal mechanism for administration.

Off-site vaccinations

The Advance Service states:

4.9 The pharmacy contractor **must obtain approval from the Commissioner** if they wish to carry out vaccination at a location that is **not** the pharmacy registered premises.

If you wish to carry out vaccinations at a location that is **NOT** the pharmacy premises, a MSForm must be completed in full for approval to be granted. Please request this form by emailing england.sepharmacycovidvacc@nhs.net the form will be sent to you. The completed form will be checked before any approval is granted. The MSForm will be available shortly and will be circulated to pharmacies to complete.

You will also need approval from the off-site location before submitting the MSForm and ensure you have appropriate processes in place. Please note more than one pharmacy could request approval at the same off site location.

We encourage you to work collaboratively with local systems, ICBs, Local Authorities and other providers, to ensure offsite activity is co-ordinated and local communications. We will share a list of off- site approved providers with ICB leads to help facilitate this.

There is no additional funding for off site vaccinations.

Distance Selling Pharmacies (DSP) can only provide off site vaccinations they cannot provide on site vaccinations.

DSP must obtain approval from the commissioner if they wish to carry out vaccinations off site.



Check you are ready to provide the service

The CPE website has useful information to help you to provide the service. You may wish to use the checklists that are available to ensure you are ready.

The checklists are:

[Pharmacy owner implementation checklist - NHS MenB Vaccination Service](#)

This checklist summarises the actions pharmacy owners need to undertake to prepare to provide the NHS MenB Vaccination Advanced Service.

[MenB vac implementation checklist - vaccinators](#)

This checklist provides suggested actions that pharmacists, pharmacy technicians and vaccinators can undertake to prepare to provide the NHS MenB Vaccination Advanced Service.


Ordering supporting resources

A guide to Meningococcal B vaccination for eligible young people (leaflet)

- Paper copies of this leaflet are available to download and order for free from [Find Public Health Resources](#) using product code [13347EN001](#).
- This leaflet will also be available in a range of accessible formats and community languages in due course.

MenB programme consent form

This MenB vaccination consent form should be used to record every MenB vaccine given. This consent form can be downloaded and ordered for free from [Find Public Health Resources](#) using product code [1334AEN001](#).



 You can read the MenB vaccine leaflet at <https://grco.de/havemenb> or by scanning the QR code.

NHS

Meningitis B vaccination consent form

Surname:	Forename:	Date of Birth:
		Gender: Male ☐ Female ☐
		Prefer not to say ☐
Address & Postcode:		Mobile Phone number:
		Email:
GP Surgery:		NHS Number:

Important medical information

Have you received Meningitis B vaccine/s previously? Dates:	☐ Yes* ☐ No
Have you had a severe anaphylactic reaction to vaccines?	☐ Yes* ☐ No
Do you take any prescribed medications?	☐ Yes* ☐ No
Do you have any long-standing medical conditions?	☐ Yes* ☐ No

* If you answered yes to any of the above, please give details:

Consent

Yes, I consent to receive the meningitis B vaccination course:

Signature (patient, parent or guardian):	Date:
--	-------

OFFICE USE ONLY							
	Date:	Time:	Site of IM injection (please circle)	Name of vaccine	Batch number & Expiry date:	Immuniser:	Location:
1 st Meningitis B vaccine as per PGD			L R				
2 nd Meningitis B vaccine as per PGD			L R				

Nurses' Comments:

© Crown copyright 2008. UK Health Security Agency gateway number: 1001101. Product code: 1334AEN001. 1p 2008. A1/A 2008. 1P/01. If you require more copies of this consent form, please visit <http://find-public-health-resources.service.gov.uk> or call 0300 121 1002

You will need to create an account to order free resources. [Sign Up](#) using your work email address to access higher order limits

Ordering supporting resources

MenB vaccination poster – under 25

A3-sized poster to display in any service offering the MenB vaccine to eligible young adults. This poster can be downloaded and ordered for free from [Find Public Health Resources](#) using product code [13349EN001](#).

MenB vaccinations card

This record card should be given to anyone who has received one dose of MenB vaccine, to remind them to attend the clinic for their second dose to complete the course. Each pack contains 25 cards, and can be downloaded and ordered for free from [Find Public Health Resources](#) using product code [13348EN001](#).

MenB digital display screens

A range of images can be downloaded for digital display screens in any service promoting or offering the MenB vaccine (see notes for links).

You will need to create an account to order free resources. [Sign Up](#) using your work email address to access higher order limits



Resources

Professional

- [Meningococcal B \(MenB\) time limited vaccination offer letter - GOV.UK](#)
- [Men B time limited offer letter: Annex A: detailed information, guidance and resources for healthcare professionals - GOV.UK](#)
- [NHS England » Community pharmacy advanced service specification: Meningococcal B vaccination service from 20 July 2026 to 31 March 2027](#)
- [Meningitis B Vaccination Service - Community Pharmacy England](#)
- [Vaccine update: issue 372, June 2026, MenB special - GOV.UK](#)
- [Meningococcal B vaccination programme for infants: information for healthcare practitioners - GOV.UK](#)
- [Meningococcal B \(MenB\) time limited vaccination offer: training slideset](#)
- [Green Book chapter 22 – Meningococcal](#)
- [MenB vaccine \(Bexsero®\) offer Autumn 2026: PGD template - GOV.UK](#)
- [Vaccine incident guidance: responding to vaccine errors - GOV.UK](#)
- SE region [incident](#) reporting form and SE region [cold chain](#) form
- [National minimum standards and core curriculum for vaccination training](#)

Public facing

- [Who is eligible for the new one-off MenB vaccine programme? \(UKHSA blog\)](#)
- [Meningitis - NHS](#)
- [A guide to Meningococcal B vaccination for eligible young people - GOV.UK](#) (main leaflet)
- [Discover the health resource library](#) (ordering leaflets, posters, consent forms and record cards)
- [Adolescent vaccination catch-up resources \(posters\) \(HPV, MenACWY, MMR\)](#) (download posters to display in pharmacies to encourage catch-up of other vaccinations)

Literature

- Wang B, Giles L, Andraweera P and others. [Long-Term Protection Against Invasive Meningococcal B Disease and Gonococcal Infection 5 Years After Implementation of Funded Childhood and Adolescent 4CMenB Vaccination Program in South Australia: An Observational Cohort and Case-Control Study](#). *Clinical Infectious Diseases*: July 11 2025, volume 81, issue 4, pages 202 to 210

Q&A

Who to Contact:

Clinical, Incident Queries and Vaccine Allocation and Supply queries

- Sussex: sxicb.primarycaremassvacc@nhs.net
- Surrey Heartlands: syheartlandsicb.svoc@nhs.net
- Thames Valley ICB: svoc-opsmanager.bob@nhs.net
- Hampshire/IOW ICB: hiowicb-hsi.vaccination.operations@nhs.net
- Kent & Medway ICB: kmicb.svoc@nhs.net

Contract Enquiries England.sepharmacycovidvacc@nhs.net

Federated Data Platform Helpdesk ssd.nationalservicedesk@nhs.net

MYA Helpdesk [NBS Helpdesk](#)

Walk In Finder nhswebsite.servicedesk@nhs.net

RAVS [Customer Service Portal - Customer Support](#)

Evaluation

South East Meningococcal B
(MenB) Vaccination Webinar
Evaluation



Thank you for attending.
Your evaluation is very much
appreciated!

Thank You



@nhsengland



company/nhsengland



england.nhs.uk